Posted by Michael Wonder on 28 Jul 2023
FDA approves second over the counter naloxone nasal spray product
28 July 2023 - Today, the US FDA approved RiVive, 3 mg naloxone hydrochloride nasal spray for over the counter, non-prescription use for the emergency treatment of known or suspected opioid overdose.
The timeline for availability and the price of this nonprescription product will be determined by the manufacturer.
